Therapeutic advances in Huntington's Disease

Deep brain stimulation in Huntington’s disease: Assessment of potential targets

(2015) Mayur Sharma et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

(2015)   LANCET NEUROLOGY

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

(2015) Ralf Reilmann et al.   MOVEMENT DISORDERS

Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease

(2015) Ana Silva et al.   Neurodegenerative Diseases

Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease

(2015) Susanna Pietropaolo et al.   NEUROPHARMACOLOGY

4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease

(2015) Rajat Sandhir et al.   SYNAPSE

Mutant huntingtin is present in neuronal grafts in huntington disease patients

(2014) Francesca Cicchetti et al.   ANNALS OF NEUROLOGY

The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?

(2014) Joana Gil-Mohapel et al.   CURRENT DRUG TARGETS

Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease

(2014) Lisa M. Stanek et al.   HUMAN GENE THERAPY

Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease

(2014) G. A. Smith et al.   HUMAN MOLECULAR GENETICS

Quadruple deep brain stimulation in Huntington’s disease, targeting pallidum and subthalamic nucleus: case report and review of the literature

(2014) D. Gruber et al.   JOURNAL OF NEURAL TRANSMISSION

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study

(2014) Victoria Gonzalez et al.   JOURNAL OF NEUROSURGERY

A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease

(2014) Adriana Prundean et al.   MOVEMENT DISORDERS

Targets for future clinical trials in Huntington's disease: What's in the pipeline?

(2014) Edward J. Wild et al.   MOVEMENT DISORDERS

Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches?

(2014) Annie Killoran et al.   MOVEMENT DISORDERS

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

(2014) H. D. Rosas et al.   NEUROLOGY

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

(2014) Jens Niewoehner et al.   NEURON

A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease

(2014) Daniel Todd et al.   PLoS One

Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease

(2013) M. Jiang et al.   HUMAN MOLECULAR GENETICS

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease

(2013) R. A. Barker et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A Small Molecule TrkB Ligand Reduces Motor Impairment and Neuropathology in R6/2 and BACHD Mouse Models of Huntington's Disease

(2013) D. A. Simmons et al.   JOURNAL OF NEUROSCIENCE

Results of the citalopram to enhance cognition in Huntington disease trial

(2013) Leigh J. Beglinger et al.   MOVEMENT DISORDERS

Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

(2013) Ralf Reilmann   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

(2013)   MOVEMENT DISORDERS

Bilateral Globus Pallidus Stimulation in Westphal Variant of Huntington Disease

(2013) Giuliana Cislaghi et al.   NEUROMODULATION

Review: The fate of cell grafts for the treatment of Huntington's disease: thepost-mortemevidence

(2013) G. Cisbani et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Treatment of Huntington’s Disease

(2013) Samuel Frank   Neurotherapeutics

A 5-year follow-up of deep brain stimulation in Huntington's disease

(2013) Jose Luis López-Sendón Moreno et al.   PARKINSONISM & RELATED DISORDERS

Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington’s Disease

(2013) Carmela Giampà et al.   PLoS One

Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons

(2013) Jun Tian et al.   Neuroscience Bulletin

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

(2012) Wolfgang Brück et al.   ACTA NEUROPATHOLOGICA

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin–proteasomal and autophagy systems

(2012) Haiqun Jia et al.   HUMAN MOLECULAR GENETICS

Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease

(2012) J. Bouchard et al.   JOURNAL OF NEUROSCIENCE

Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology

(2012) M. J. Armstrong et al.   NEUROLOGY

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington’s disease

(2012) J. Nithianantharajah et al.   NEUROSCIENCE

Targeting Neuro-Inflammatory Cytokines and Oxidative Stress by Minocycline Attenuates Quinolinic-Acid-Induced Huntington’s Disease-Like Symptoms in Rats

(2012) Harikesh Kalonia et al.   NEUROTOXICITY RESEARCH

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

(2012) A. Di Pardo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

(2012) M. Garriga-Canut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Constitutive Upregulation of Chaperone-Mediated Autophagy in Huntington's Disease

(2011) H. Koga et al.   JOURNAL OF NEUROSCIENCE

Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin

(2011) Jeffrey B Carroll et al.   MOLECULAR THERAPY

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease

(2011) Jing Fan et al.   NEUROBIOLOGY OF DISEASE

Dopamine and Glutamate in Huntington's Disease: A Balancing Act

(2010) Véronique M. André et al.   CNS Neuroscience & Therapeutics

Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Mannerin Vitroandin Vivo

(2010) Justin Legleiter et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

External Globus Pallidus Stimulation Modulates Brain Connectivity in Huntington's Disease

(2010) Noémie Ligot et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease

(2010) Dénes Zádori et al.   JOURNAL OF NEURAL TRANSMISSION

BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice

(2010) Y. Xie et al.   JOURNAL OF NEUROSCIENCE

A futility study of minocycline in Huntington's disease

(2010) Merit Cudkowicz   MOVEMENT DISORDERS

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice

(2010) Danielle A. Simmons et al.   NEUROBIOLOGY OF DISEASE

Modulation of Mutant Huntingtin N-Terminal Cleavage and Its Effect on Aggregation and Cell Death

(2010) Katrin Juenemann et al.   NEUROTOXICITY RESEARCH

Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease

(2010) Carmela Giampà et al.   PLoS One

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

(2009) Ferdinando Squitieri et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Mutant huntingtin interacts with  -tubulin and disrupts vesicular transport and insulin secretion

(2009) R. Smith et al.   HUMAN MOLECULAR GENETICS

Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells

(2009) Tamara Ratovitski et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease

(2009) M. Y. Heng et al.   JOURNAL OF NEUROSCIENCE

Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies

(2008) S Sarkar et al.   CELL DEATH AND DIFFERENTIATION

A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease

(2008) Samuel Frank et al.   CLINICAL NEUROPHARMACOLOGY

Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells

(2008) Rodrigo A. Quintanilla et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Symptomatic treatment of Huntington disease

(2008) Octavian R. Adam et al.   Neurotherapeutics